May 10, 2024 11:22 AM EDT

iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar

Plus, news about AnaptysBio, Alzamend, AEON Biopharma and argenx:

iTeos Therapeutics’ $120M offering: The immuno-oncology company

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

iTeos to raise $120M; Xbrane and STA­DA to out-li­cense Lu­cen­tis biosim­i­lar